Streetbeat News

TSVT

2seventy bio, Inc.

https://www.2seventybio.com

Industry

Biotechnology

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Open

5.02

Mkt cap

254M

Volume

43K

High

5.04

P/E Ratio

-1.53

52-wk high

6.40

Low

4.88

Div yield

N/A

52-wk low

1.53

Pomerantz Law Firm is investigating claims on behalf of investors of 2seventy bio, Inc. (NASDAQ:TSVT). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 12, 2024 | 11:45 pm

2seventy bio, Inc. (NASDAQ:TSVT) held its Q3 2024 earnings conference call on November 12, 2024. Key participants included CEO Chip Baird and CFO Vicki Eatwell, with analysts from Citi and Leerink Partners attending.

Portfolio Pulse from

November 12, 2024 | 4:30 pm

2seventy bio, Inc. (TSVT) reported a Q3 loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is an improvement from a $1 per share loss a year ago.

Portfolio Pulse from

November 12, 2024 | 3:00 pm

Pomerantz Law Firm is investigating claims on behalf of investors of 2seventy bio, Inc. (NASDAQ:TSVT). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 06, 2024 | 9:45 pm

Novo Nordisk's hemophilia drug Alhemo receives a positive opinion from the European Medicines Agency's CHMP, recommending its approval as a once-daily treatment for hemophilia A or B with inhibitors. The drug has shown significant efficacy in reducing bleeding episodes.

Portfolio Pulse from Vandana Singh

October 18, 2024 | 5:21 pm

Several healthcare stocks experienced significant price movements in Thursday's after-market session. Renovaro, AIM ImmunoTech, Phathom Pharmaceuticals, Outlook Therapeutics, Roivant Sciences, and Century Therapeutics saw gains, while Avinger, Carmell, Ainos, Theriva Biologics, 2seventy bio, and Bone Biologics experienced losses.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:31 pm

2seventy bio and Bristol Myers Squibb have halted the Phase 3 trial of Abecma for newly diagnosed myeloma patients, aiming to save $80 million and reach profitability by 2025. Despite the trial halt, Abecma's revenue is expected to grow, supported by FDA approval for earlier use. Both companies share profits and losses from Abecma equally.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 3:56 pm

2seventy anticipates a 30% increase in Q3 US revenue for Abecma from Q2's $54M, with strong demand indicated by double-digit growth in new patients. The company is focused on sustaining Abecma's success into 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:05 am

2seventy bio plans to conserve over $80 million in near-term expenditures by making a decision on the KarMMa-9 study. This move is expected to accelerate the company's path to breakeven by 2025.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:04 am

2seventy bio and Bristol Myers Squibb have decided to discontinue enrollment in the Phase 3 KarMMa-9 study due to improvements in the NDMM treatment landscape and a review of the business case.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.